Resistance to everolimus may be
linked to feedback activation of the
PI3K pathway
Buparlisib + Fulvestrant Controls Tumor Growth in
Preclinical Models of Everolimus-Resistant Breast Cancer
Buparlisib + fulvestrant controls tumor growth in an
everolimus-resistant* breast cancer xenograft model
(ZR75-1)
1
ZR75-1: wild-type PIK3CA, PTEN mutation ,and loss of function.
* Resistance to everolimus acquired by daily treatment with everolimus 10 mg for >45 days
Figure reproduced with permission of Dr O’Brien from SABCS 2013; PD1–5 (Poster).
1. O’Brien HA, et al
. SABCS 2013:PD1
−5 (Poster).
Buparlisib
Everolimus
Tumor volume (mm
3
)
Time of treatment (days)
0
42
6
12 18 24 30 36
0
400
200
1000
800
600
Buparlisib + fulvestrant
Everolimus
